FDA approves first epoetin alfa biosimilar

Author(s):

first epoetin alfa biosimilar

On May 15, the U.S. Food and Drug Administration (FDA) approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.

Read more via FDA.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here